Godavari Biorefineries Limited (GBL), one of India’s leading ethanol producers and a global pioneer in bio-based chemicals, has posted resilient financial results for Q1 FY26, overcoming seasonal challenges in certain segments.
The company reported revenue from operations of ₹534 crore, up from ₹522.5 crore in Q1 FY25. EBITDA stood at ₹6.5 crore, with the Bio-based Chemicals segment registering a robust 43% year-on-year EBITDA growth to ₹12.53 crore. However, profit after tax (PAT) declined to ₹16 crore from ₹26.1 crore in the same period last year.
Ethanol production reached 26,057 KL during the quarter, aided by the restoration of B-heavy molasses-based ethanol production under the Ethanol Blending Programme (EBP). The company also announced progress on its upcoming grain-based ethanol capacity, expected to add a new growth driver.
On the innovation front, GBL made significant progress in drug discovery. Its European patent for a novel anti-cancer molecule has been validated in Spain, the UK, and as a Unitary Patent across several EU member states. Safety trials concluded without dose-limiting toxicity. Additionally, the company secured a Chinese patent for another anti-cancer compound, HYDROXY-1,4-NAPHTHALENEDIONE, which has shown strong in-vitro efficacy against breast, prostate, and other cancers.
CMD Samir Somaiya highlighted that GBL’s strategic focus remains on strengthening its bio-based chemicals portfolio through debottlenecking, developing specialty chemicals, expanding multi-feedstock ethanol capabilities, and investing in R&D to ensure sustainable, long-term growth.